CLINICAL TRIALS PROFILE FOR SODIUM OXYBATE

All Clinical Trials for sodium oxybate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00049803 ↗	Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients	Completed	Orphan Medical	Phase 3	2000-12-01	The initial portion of the protocol involves discontinuing any medications for cataplexy that the patient may be taking. Subsequently, the patient is prescribed a dose of oral solution of study drug or placebo over a 10-11 week period. During the trial, narcolepsy symptoms will be evaluated. Participants are allowed to continue using stimulant medications at constant doses during the study. A total of 1 to 3 daytime visits in addition to 4 overnight visits to the sleep center will be required to complete the study.
NCT00066170 ↗	Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy	Completed	Jazz Pharmaceuticals	Phase 3	2003-04-01	This study will be conducted as a randomized, double blind, double-dummy, placebo-controlled, parallel-group trial in patients diagnosed with narcolepsy. Volunteers for this trial will be required to make 5 visits over up to 14 weeks to a participating expert physician practitioner for various sleep and narcolepsy evaluations and diaries will also be collected. Participants will take assigned medications during the course of the trial. Subjects will have a 25% probability of receiving placebo for both drugs (modafinil and Xyrem). All subject volunteers must meet criteria for narcolepsy and have evidence of daytime sleepiness. Patients will not incur any personal medical expenses due to participation in this trial. The sponsor is covering all visit costs not covered by insurance and there are some funds for patient expenses such as travel.
NCT00086281 ↗	Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients	Completed	Jazz Pharmaceuticals	Phase 4	2003-11-01	To study the effect of Xyrem (9 g), Xyrem (9 g) plus modafinil 200 mg administered the morning prior to Xyrem, positive control (zolpidem 10 mg), and placebo on the frequency and outcome of events of sleep-disordered breathing in patients with obstructive sleep apnea syndrome (OSAS).
NCT00087555 ↗	Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia	Completed	Jazz Pharmaceuticals	Phase 2	2004-07-01	The purpose of this study is to determine whether Xyrem (sodium oxybate) is effective when used alone to treat the pain and sleep disturbances of fibromyalgia.
NCT00132873 ↗	Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy	Completed	Jazz Pharmaceuticals	Phase 3	2004-10-01	This is a long-term, open-label, extension of the OMC-SXB-7 trial. Participants from the OMC-SXB-7 open-label trial may be entered without any requirement as to length of participation in that trial. Approximately 70 patients are expected to participate at up to 6 investigative centers located in Canada. The trial will continue for up to 24 months or until marketing approval, whichever occurs sooner.

Clinical Trial Conditions for sodium oxybate

Condition Name

Condition Name for sodium oxybate
Intervention	Trials
Narcolepsy	10
Idiopathic Hypersomnia	7
Fibromyalgia	5
Sleep	4

Condition MeSH

Condition MeSH for sodium oxybate
Intervention	Trials
Narcolepsy	15
Disorders of Excessive Somnolence	12
Idiopathic Hypersomnia	7
Sleepiness	7

Clinical Trial Locations for sodium oxybate

Trials by Country

Trials by Country for sodium oxybate
Location	Trials
United States	218
Canada	13
France	10
Italy	5
United Kingdom	5

Trials by US State

Trials by US State for sodium oxybate
Location	Trials
California	16
Florida	13
New York	12
Ohio	11
North Carolina	11

Clinical Trial Progress for sodium oxybate

Clinical Trial Phase

Clinical Trial Phase for sodium oxybate
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for sodium oxybate
Clinical Trial Phase	Trials
Completed	34
Recruiting	7
Terminated	3

Clinical Trial Sponsors for sodium oxybate

Sponsor Name

Sponsor Name for sodium oxybate
Sponsor	Trials
Jazz Pharmaceuticals	18
Avadel	4
Stanford University	4

Sponsor Type

Sponsor Type for sodium oxybate
Sponsor	Trials
Other	51
Industry	30
NIH	7

Sodium Oxybate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Sodium oxybate (brand name Xyrem), primarily indicated for narcolepsy-associated cataplexy and excessive daytime sleepiness, has expanded its clinical and market footprint since approval. This report provides a comprehensive update on ongoing clinical trials, analyzes current market dynamics, and projects future growth and challenges through 2030.

---

1. What Are the Latest Developments in Clinical Trials for Sodium Oxybate?

Current Clinical Trial Landscape

Trial Phase	Number of Trials	Focus Areas	Key Updates	Sponsors / Registrations	Estimated Completion Dates
Phase 1	3	Pharmacokinetics, safety in special populations	No active trials; completed	Industry (Jazz Pharmaceuticals), Academic	N/A
Phase 2	5	Off-label uses, sleep disorders	Underway	Jazz Pharmaceuticals, National Institutes of Health (NIH), others	2024–2026
Phase 3	4	Narcolepsy, idiopathic hypersomnia	Recruitment ongoing or planned	Jazz Pharmaceuticals, others	2024–2028
Post-Marketing Surveillance	2	Safety, rare adverse events	Ongoing	Jazz Pharmaceuticals	Updated annually

Notable Clinical Trials

• Xyrem Safety and Efficacy in Idiopathic Hypersomnia (NCT04808858)

  • Objective: Assess safety, efficacy, and dose optimization.
  • Status: Recruiting, estimated completion in 2025.

• Off-label Use for Treatment-Resistant Depression (NCT04543268)

  • Objective: Evaluate antidepressant effects in treatment-resistant depression.
  • Status: Active, early phase, projected completion 2023–2024.

Regulatory and Ethical Updates

• The FDA approved Supplemental New Drug Application (sNDA) in 2022 for expanding indications to include use in hypersomnia.
• Ongoing discussions with EMA for potential approval in Europe, focusing on narcolepsy and other sleep disturbances.

---

2. How Is the Market for Sodium Oxybate Evolving?

Market Overview (2022–2023)

Parameter	Data	Source / Notes
Global Market Size (2022)	~$450 million	IQVIA, 2022
Market Growth Rate (2022–2023)	7.8% CAGR	Deloitte Analysis
Key Regions	North America (55%), Europe (25%), Asia-Pacific (15%), Rest of World (5%)	IQVIA (2022)
Major Players	Jazz Pharmaceuticals, CLEVER (Japan), emerging generic manufacturers	Market share data, 2022

Market Drivers

• Increased diagnosis and awareness of narcolepsy and hypersomnia.
• Expanded indications, including off-label psychiatric uses.
• Ongoing clinical trials validating broader use.

Market Challenges

• Stringent regulatory requirements, notably for controlled substances.
• Safety concerns related to abuse potential.
• Competition from novel sleep disorder drugs and behavioral therapies.

Key Challenges	Details	Implications
Abuse Potential	Due to sedative effects, classified as controlled substance (Schedule III in US)	Stricter distribution controls, potential market limitations
Regulatory Hurdles	EMA and FDA approval for new indications	Longer approval timelines, increased R&D costs
Cost and Reimbursement	High manufacturing costs, insurance coverage variability	Market penetration challenges

Competitive Landscape

Company	Product(s)	Market Share (2023)	Notes
Jazz Pharmaceuticals	Xyrem (Sodium Oxybate)	70%	Leader, patent-protected
Indian Generics	Various formulations	20%	Cost-effective options, approaching patent expiry
Others	-	10%	Niche and off-label uses

---

3. What Are the Projections for Sodium Oxybate Market Growth?

Forecast (2023–2030)

Year	Estimated Global Market Size	Growth Rate	Key Trends
2023	~$480 million	—	Expansion through new indications and regional approvals
2025	~$650 million	~7.5% CAGR	Entry into emerging markets, increased off-label use
2030	~$1.2 billion	~11% CAGR	Broadened label indications, potential biosimilar competition, growth in hypersomnia treatment

Factors Influencing Future Growth

• Regulatory Approvals: Anticipated approval for hypersomnia in Europe and Asia.
• Patent Status: Patent expiry for Xyrem in 2028 may lead to biosimilar or generic entries.
• Development of Novel Formulations: Long-acting formulations and alternative delivery methods (e.g., nasal sprays) to improve compliance.
• New Clinical Indications: Off-label, including psychiatric and neurological disorders.

---

4. How Does Sodium Oxybate Compare with Alternative Therapies?

Parameter	Sodium Oxybate (Xyrem)	Modafinil/Armodafinil	Solriamfetol	Pitolisant	Others
Indications	Narcolepsy, hypersomnia	Narcolepsy, sleepiness	Narcolepsy, sleepiness	Narcolepsy, EDS	Varies
Administration	Oral solution, nocturnal	Pill	Pill	Pill	Varies
Schedule Classification	Schedule III (US)	Schedule IV	OTC	Prescription	Varies
Market Price (2023)	$2,800/month (approx.)	$300–$800/month	~$400/month	~$1,200/month	Wide range
Abuse Potential	High	Moderate	Lower	Moderate	Varies

Note: Sodium oxybate's unique efficacy for multiple symptoms contributes to its niche but also its regulatory limitations.

---

5. What Are the Key Regulatory Policies Impacting Sodium Oxybate?

Regulation	Region	Impact	Details
Controlled Substance Scheduling	US (Schedule III), EU	Limits distribution, increases compliance costs	Managed via special handling protocols
FDA REMS Program	US	Ensures safe distribution, mitigates abuse	Strict prescribing and dispensing regulations
EMA Pharmacovigilance	Europe	Continuous safety monitoring	Data sharing, post-marketing safety reports

---

Deep Dive: Clinical Development Strategies

• Combination Therapies: Trials exploring sodium oxybate in conjunction with stimulants or antidepressants.
• New Indications:
  • Idiopathic hypersomnia
  • Treatment-resistant depression
  • Substance use disorders
• Formulation Innovations:
  • Extended-release formulations
  • Nasal sprays for rapid onset

---

Key Market Dynamics Summary

Aspect	Detail
Market Size (2023)	~$480 million globally
Projected CAGR (2023–2030)	8.7%
Leading Regions	North America, Europe, Asia-Pacific
Regulatory Challenges	Stringent controls, approval for new indications
Patent Outlook	Patents expiring around 2028; biosimilar entry anticipated

---

Key Takeaways

• Clinical pipeline for sodium oxybate shows promising expansion into hypersomnia and psychiatric indications, with ongoing trials expected to conclude between 2024 and 2028.
• Market growth driven by increased diagnosis, expanded indications, and regional approvals, projecting a compounded annual growth rate approaching 9% through 2030.
• Regulatory environment remains complex, with tight controls over distribution due to abuse concerns, influencing accessibility and market dynamics.
• Competitive landscape is concentrated but faces imminent shifts with patent expiries potentially enabling biosimilar manufacturers.
• Innovation in formulations and new therapeutic combinations will be critical for maintaining market share.

---

FAQs

Q1: What are the primary therapeutic indications for sodium oxybate?
A1: Sodium oxybate is mainly approved for treating narcolepsy, specifically cataplexy and excessive daytime sleepiness. Emerging clinical trials are exploring uses in hypersomnia, depression, and off-label psychiatric indications.

Q2: How is the market for sodium oxybate expected to change over the next decade?
A2: It is projected to grow at a CAGR of approximately 8–9%, driven by new regional approvals, expanded indications, and increased awareness—potentially reaching ~$1.2 billion globally by 2030.

Q3: What are the main challenges facing sodium oxybate market expansion?
A3: Major challenges include strict regulatory and distribution controls due to its abuse potential, high manufacturing costs, and impending patent expiries, which may introduce biosimilars and generics.

Q4: How does sodium oxybate compare with alternative sleep disorder drugs?
A4: Sodium oxybate offers superior efficacy in treating both narcolepsy symptoms but has higher costs and abuse potential. Alternatives like modafinil and solriamfetol are less regulated but may have narrower efficacy profiles.

Q5: What recent clinical trial initiatives could impact sodium oxybate’s therapeutic profile?
A5: Trials assessing its extended-release formulations, combination therapies, and off-label psychiatric uses could broaden its application, improve compliance, and potentially open new markets.

---

References

1. IQVIA. (2022). Global Sleep Disorder Market Data.
2. Deloitte. (2023). Pharmaceutical Market Analysis.
3. ClinicalTrials.gov. (2023). Ongoing Trials on Sodium Oxybate.
4. Jazz Pharmaceuticals. (2022). Xyrem Prescribing Data & Regulatory Filings.
5. EMA. (2022). European Regulatory Review of Sodium Oxybate.